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HeBACKGROUND The beneﬁts and risks of prolonged dual antiplatelet therapy may be different for patients with acute
myocardial infarction (MI) compared with more stable presentations.
OBJECTIVES This study sought to assess the beneﬁts and risks of 30 versus 12 months of dual antiplatelet therapy
among patients undergoing coronary stent implantation with and without MI.
METHODS The Dual Antiplatelet Therapy Study, a randomized double-blind, placebo-controlled trial, compared 30
versus 12 months of dual antiplatelet therapy after coronary stenting. The effect of continued thienopyridine on ischemic
and bleeding events among patients initially presenting with versus without MI was assessed. The coprimary endpoints
were deﬁnite or probable stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE). The
primary safety endpoint was GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Arteries) moderate or severe bleeding.
RESULTS Of 11,648 randomized patients (9,961 treated with drug-eluting stents, 1,687 with bare-metal stents), 30.7%
presented withMI. Between 12 and 30months, continued thienopyridine reduced stent thrombosis comparedwith placebo in
patients with and without MI at presentation (MI group, 0.5% vs. 1.9%, p < 0.001; no MI group, 0.4% vs. 1.1%, p < 0.001;
interaction p¼ 0.69). The reduction inMACCE for continued thienopyridine was greater for patients withMI (3.9% vs. 6.8%;
p < 0.001) compared with those with no MI (4.4% vs. 5.3%; p ¼ 0.08; interaction p ¼ 0.03). In both groups, continued
thienopyridine reduced MI (2.2% vs. 5.2%, p < 0.001 for MI; 2.1% vs. 3.5%, p < 0.001 for no MI; interaction p ¼ 0.15) but
increased bleeding (1.9% vs. 0.8%, p ¼ 0.005 for MI; 2.6% vs. 1.7%, p ¼ 0.007 for no MI; interaction p ¼ 0.21).
CONCLUSIONS Compared with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent
thrombosis and MI in patients with and without MI, and increased bleeding. (The Dual Antiplatelet Therapy Study
[The DAPT Study]; NCT00977938) (J Am Coll Cardiol 2015;65:2211–21) © 2015 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
MACCE = major adverse
cardiovascular and
cerebrovascular events(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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2212T reatment with dual antiplatelettherapy using the combination of aP2Y12 receptor inhibitor and aspirin
is mandatory after percutaneous coronary
intervention (PCI) with stents. In the Dual
Antiplatelet Therapy (DAPT) Study, patients
who were free from major ischemic or
bleeding events at 1 year after PCI had signif-
icant reductions in stent thrombosis and
myocardial infarction (MI) but increases in
moderate or severe bleeding when treated
with continued dual antiplatelet therapy
for a total of 30 months as compared with12 months (1). Patients presenting with acute MI
may derive particular beneﬁt from treatment with
extended-duration dual antiplatelet therapy, because
of a greater risk of subsequent MI and stent throm-
bosis (2,3). Consequently, current guidelines gener-
ally recommend a longer treatment period in
patients undergoing PCI for MI regardless of stent
type (bare-metal stent [BMS] or drug-eluting stent
[DES]) compared with those undergoing PCI for less
acute indications (4–6).SEE PAGE 2222However, patients with stable coronary disease
are also at risk for future acute ischemic events, and
may also beneﬁt from prolonged dual antiplatelet
therapy (7). Whether those undergoing PCI for
MI derive a similar or greater beneﬁt from continued
thienopyridine treatment beyond 12 months com-
pared with those undergoing PCI for more stablech is sponsored by the Harvard Clinical Research Institute and fun
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the treatment effect of 30 versus 12 months of dual
antiplatelet therapy after coronary stenting among
subjects who presented with and without acute MI.
METHODS
DESIGN. The DAPT Study design has previously been
described (8). Brieﬂy, this double-blind, international,
multicenter, randomized, placebo-controlled trial
compared the beneﬁts and risks of 30 versus 12months
of thienopyridine therapy (clopidogrel or prasugrel)
when prescribed in addition to aspirin following cor-
onary stenting with either DES or BMS. The trial
incorporated ﬁve individual component studies into a
single, uniform randomized trial, with enrollment of
subjects either by the Harvard Clinical Research
Institute or through 1 of 4 post-marketing surveillance
studies. The results comparing randomized treat-
ments in the overall DES-treated (1) and BMS-treated
(9) cohorts have been reported previously. The insti-
tutional review board at each participating institution
approved the study. The purpose of the present study
was to examine whether the ischemic beneﬁts and
bleeding risks associated with 30 versus 12 months of
dual antiplatelet therapy are consistent among pa-
tients presenting with versus without acute MI. These
analyses were not pre-speciﬁed in the original
protocol.
STUDY POPULATION AND PROCEDURES. We enrolled
patients with coronary artery disease who were can-
didates for dual antiplatelet therapy and who receivedded by Abbott, Boston Scientiﬁc Corporation, Cordis
aceuticals Partnership, Eli Lilly and Company, and
uman Services (1RO1FD003870-01). Dr. Yeh is on the
ad Sciences and Merck. Dr. Kereiakes has served as a
d personal fees from Amarin, AstraZeneca, Bayer,
e, Eli Lilly, Merck-Sharpe-Dohme, Novartis, Otsuka,
mpany, and Orexigen; and has received grants from
stitution from Abbott, Biotronik, Boston Scientiﬁc,
nd speaker fees from AstraZeneca, Eli Lilly, Abbott,
ved personal fees from Medtronic and Abbott; and
Medtronic, Boston Scientiﬁc, Cordis Inc., and Abbott
ng the conduct of the study. Dr. Cohen has received
hi-Sankyo, Abbott Vascular, Boston Scientiﬁc, and
, and Medtronic. Dr. Tanguay has received personal
illy, GlaxoSmithKline, and Sanoﬁ; personal fees from
tt has received grants and personal fees from Astra-
m Eisai, Merck, and Sanoﬁ; and personal fees from
esearch Institute. Dr. Massaro has received personal
study. Dr. Mauri has received institutional research
kyo, and Sanoﬁ/Bristol-Myers Squibb; and personal
hors have reported that they have no relationships
Guest Editor for this paper.
ntin Fuster.
r. Valentin Fuster.
2, 2015, accepted March 4, 2015.
FIGURE 1 Enrollment, Randomization, and Follow-Up of Patients in the Dual Antiplatelet Therapy Study Stratiﬁed by
Acute Myocardial Infarction Status at Presentation
3,576 Patients  With MI
1,771 
Randomized 
to Placebo
1,711 (94.8%) 
Clinical Follow-
Up Available at 
30 Months
1,805 
Randomized to 
Continued 
Thienopyridine
94 Not 
Available for 
Follow-Up at 
30 Months‡
189 Not 
Available for 
Follow-Up at 
30 Months‡
3,868 (95.3%) 
Clinical Follow-
Up Available at 
30 Months
25,682 Stent-Treated Patients 
Enrolled
N = 7,119 with MI
N = 18,563 without MI
8,072 Patients Without MI
4,057 
Randomized to 
Continued 
Thienopyridine
4,015 
Randomized 
to Placebo
111 Not 
Available for 
Follow-Up at 
30 Months‡
175 Not 
Available for 
Follow-Up at 
30 Months‡
5,844 Were Not Eligible for Randomization:
18 Did Not Meet Enrollment Criteria    
2,971 Had Events*
335 Died
675 Had MI
202 Had Stroke
135 Had Stent Thrombosis
1,845 Had Revascularization
665 Had Severe/Moderate GUSTO Bleeding 
1,343 Were Noncompliant
1,512  Had Other Exclusion Criteria
8,190 Were Eligible but Not Randomized:
6,127 Withdrew Consent
1,970 Had Randomization Visit Out of  Window/Lost  to Follow-Up
38 Had Other Reasons†
55 Had Unknown Reason
11,648 Were Randomized at 12 Months
1,660 (93.7%) 
Clinical Follow-
Up Available at 
30 Months
3,840 (95.6%) 
Clinical Follow-
Up Available at 
30 Months
Patients were enrolled within 72 h after placement of either a bare-metal or drug-eluting stent, and received open-label treatment with aspirin
and thienopyridine for 12 months. Eligible subjects were then randomized to thienopyridine or placebo, while continuing aspirin, and followed-
up for an additional 18 months (months 12 to 30). *Subjects may have >1 event. †Site terminated participation, randomization target met
before subject follow-up, or subject not recognized to be eligible by site. ‡Subjects withdrew consent, were lost to follow-up, moved, were
incarcerated, or were prematurely exited from the study. GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator for
Occluded Arteries; MI ¼ myocardial infarction.
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2213treatment with Food and Drug Administration–
approved DES and BMS devices. Patients provided
written informed consent and were enrolled with-
in 3 days of stent placement. Stent treatment was
performed according to site standards of care.
DES types included sirolimus-eluting stent (Cypher,
Cordis, Bridgewater, New Jersey), zotarolimus-eluting
stent (Endeavor, Medtronic, Minneapolis, Minnesota),
paclitaxel-eluting stent (TAXUS, Boston Scientiﬁc,
Marlborough, Massachusetts), and everolimus-eluting
stents (Xience, Abbott Vascular, Santa Clara,California; PROMUS, Boston Scientiﬁc). For this anal-
ysis, all randomized DES- and BMS-treated patients
were included.
All patients received open-label aspirin plus thie-
nopyridine for the ﬁrst 12 months after stent implan-
tation. In 1 of the contributing studies (10), all patients
received prasugrel under an Investigational Device
Exemption from the Food and Drug Administration. In
the remaining 4 contributing studies, the selection of
thienopyridinewas left to the discretion of the treating
physician. At 12 months, patients who had not had a
TABLE 1 Baseline Characteristics of Randomized Patients Initially Presenting
With Versus Without Acute Myocardial Infarction
Myocardial Infarction
at Presentation
(n ¼ 3,576)
No Myocardial Infarction
at Presentation
(n ¼ 8,072)
Thienopyridine
(n ¼ 1,805)
Placebo
(n ¼ 1,771)
Thienopyridine
(n ¼ 4,057)
Placebo
(n ¼ 4,015)
Patients
Age, yrs 57.9  10.5 57.7  10.5 63.0  9.8 62.8  9.8
Female 22.4 21.2 25.9 27.2
Nonwhite race 8.9 7.9 8.6 8.7
Weight, kg 89.7  19.1 90.8  19.0 91.6  19.8 91.2  19.5
BMI 29.8  5.5 30.0  5.6 30.7  5.8 30.6  5.8
Diabetes mellitus 20.8 21.0 33.7 32.1
Hypertension 59.8 56.4 80.5 79.7
Cigarette smoker 41.8 41.8 21.0 21.0
Stroke or TIA 2.1 2.5 4.0 4.0
Congestive heart failure 3.0 2.9 5.4 5.0
Peripheral arterial disease 2.6 3.2 6.8 7.0
Prior PCI 16.4 15.4 34.0 35.7
Prior CABG 4.1 5.5 13.4 13.3
Prior myocardial infarction 19.1 20.0 22.8 21.7
Indication for PCI
Myocardial infarction 100.0 100.0 0.0 0.0
STEMI 46.8 47.2 0.0 0.0
NSTEMI 53.2 52.9 0.0 0.0
Unstable angina 0.0 0.0 22.6 22.6
Stable angina 0.0 0.0 51.3 51.5
Other 0.0 0.0 26.2 25.9
Any risk factor for stent
thrombosis*
100.0 100.0 31.1 31.7
Renal insufﬁciency or failure 3.5 2.6 4.7 4.3
LVEF <30% 2.6 2.0 1.8 1.7
>2 vessels stented 0.2 0.3 0.4 0.6
>2 lesions per vessel 1.6 1.3 1.8 2.0
Lesion length $30 mm 10.2 8.8 9.2 10.0
Bifurcation lesion 5.6 6.2 6.5 6.2
In-stent restenosis of DES 1.4 1.4 3.3 3.5
Vein graft stented 1.7 2.4 2.9 3.2
Unprotected left main stented 0.2 0.3 0.4 0.5
Thrombus-containing lesion 37.4 35.1 3.7 4.0
Prior brachytherapy 0.2 0.1 0.3 0.3
Thienopyridine at randomization
Clopidogrel 66.4 65.6 69.2 69.5
Prasugrel 33.6 34.4 30.8 30.5
DES 72.6 72.2 91.5 91.2
Type of DES at index procedure
Sirolimus 8.3 7.8 12.6 12.1
Zotarolimus 12.0 11.4 13.1 13.0
Paclitaxel 28.3 30.2 26.4 25.4
Everolimus 49.8 48.5 45.6 47.5
>1 type 1.6 2.1 2.3 2.1
No. of treated lesions 1.3  0.5 1.2  0.5 1.3  0.6 1.3  0.5
No. of treated vessels 1.1  0.3 1.1  0.3 1.1  0.3 1.1  0.3
No. of stents 1.4  0.7 1.4  0.7 1.5  0.8 1.5  0.7
Minimum stent diameter
<3 mm 37.2 37.3 46.1 45.8
$3 mm 62.8 62.7 53.9 54.2
Total stent length, mm 27.6 27.0 27.0 26.9
Continued on the next page
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2214major adverse cardiovascular or cerebrovascular event
(MACCE) (deﬁned as the composite of death, MI,
or stroke), repeat revascularization, or moderate or
severe bleeding and had been compliant with thieno-
pyridine therapy (deﬁned as having taken 80% to
120% of the drug without an interruption of longer
than 14 days) were randomized in a 1:1 ratio to
continued thienopyridine or to placebo for an addi-
tional 18 months. Both groups continued aspirin
therapy.
Computer-generated randomization was stratiﬁed
according to stent type (DES vs. BMS), hospital site,
thienopyridine type, and presence or absence of at
least 1 pre-speciﬁed clinical- or lesion-related stent
thrombosis risk factor, including presentation with
MI (8). Acute MI at the time of PCI was deﬁned as the
presence of ischemic symptoms at rest and lasting
>10 minutes before index procedure and/or electro-
cardiogram evidence of ischemia, in conjunction with
elevated levels of a cardiac biomarker of necrosis
(creatine kinase-MB or troponin T or I greater than
the upper limit of normal). If creatine kinase-MB
or troponin was not available, total creatine kinase
>2 times the upper limit of normal was also consid-
ered to constitute MI.
ENDPOINTS. The coprimary effectiveness endpoints
of the DAPT Study were the incidence of deﬁnite or
probable stent thrombosis according to the Academic
Research Consortium deﬁnitions (11) and incidence of
MACCE in all randomized patients at 12 to 30 months
post-index procedure. The primary safety endpoint
was moderate or severe bleeding during this same
time period as assessed according to the GUSTO
(Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Arteries) classiﬁca-
tion (12). Bleeding was also ascertained according to
the Bleeding Academic Research Consortium deﬁni-
tions (13). Secondary endpoints of the study included
MI, according to the Academic Research Consortium
deﬁnition, which was further segregated into those
occurring in association with stent thrombosis and
those not related to stent thrombosis.
All potential endpoint events were adjudicated by
an independent Clinical Events Committee masked to
treatment assignment. An independent central Data
Safety Monitoring Board reviewed data from all sub-
jects at regular intervals.
STATISTICAL ANALYSIS. We compared Kaplan-Meier
estimates of endpoint events occurring between 12
and 30 months after PCI among patients with and
without acute MI at presentation, irrespective of
treatment arm using the log-rank test. Patients not
experiencing the coprimary endpoints 12 to 30 months
TABLE 1 Continued
Myocardial Infarction
at Presentation
(n ¼ 3,576)
No Myocardial Infarction
at Presentation
(n ¼ 8,072)
Thienopyridine
(n ¼ 1,805)
Placebo
(n ¼ 1,771)
Thienopyridine
(n ¼ 4,057)
Placebo
(n ¼ 4,015)
Lesions, n 2,259 2,207 5,310 5,197
Treated vessel
Native coronary artery lesions 98.0 97.2 96.8 96.8
Left main 0.2 0.4 0.9 0.9
Left anterior descending 36.7 34.5 41.4 41.1
Right 38.6 38.3 32.4 32.1
Circumﬂex 22.4 24.1 22.1 22.8
Venous graft 1.7 2.6 2.6 2.7
Arterial graft 0.3 0.2 0.6 0.5
In-stent restenosis 1.9 1.5 4.0 4.4
Extreme tortuosity 3.1 2.9 4.8 3.9
Heavy calciﬁcation 5.8 4.9 9.3 8.5
Modiﬁed ACC or AHA lesion
class B2 or C
52.9 53.9 40.2 39.4
Values are mean  SD or %, unless otherwise noted. *Stent thrombosis risk factors include those listed as well as
presentation with acute myocardial infarction at index procedure.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; BMI ¼ body mass index; CABG ¼
coronary artery bypass graft; DES ¼ drug-eluting stent; LVEF ¼ left ventricular ejection fraction; NSTEMI ¼ non-
ST segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST segment
elevation myocardial infarction; TIA ¼ transient ischemic attack.
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2215post-index procedure were censored at the time of last
known contact or 30 months, whichever was earlier.
Kaplan-Meier estimates of endpoint events were
also generated for each treatment arm among pa-
tients with and without MI. The effects of continued
thienopyridine versus placebo for patients with and
without MI were assessed using Cox proportional
hazards regression models, and are expressed as
hazard ratios (HRs) and associated 95% conﬁdence
intervals (CIs). The consistency of the treatment
effect between patients with and without MI was
evaluated through the inclusion of randomized
treatment-by-MI status interaction terms. Further-
more, among patients with and without MI, explor-
atory sensitivity analyses were performed to assess
the consistency of treatment effect among DES-
versus BMS-treated patients for stent thrombosis, and
among patients treated with clopidogrel versus pra-
sugrel at randomization for stent thrombosis, MI, and
bleeding. Finally, for the endpoints of stent throm-
bosis and MI, additional analyses were performed
excluding paclitaxel-eluting stents, which have been
associated with higher rates of adverse stent-related
ischemic events compared with other DESs (14).
All analyses were performed on randomized sub-
jects according to the intention-to-treat principle. All
statistical analyses were conducted at Harvard Clin-
ical Research Institute with the use of SAS version 9.2
(SAS Institute Inc., Cary, North Carolina). A 2-sided
p value of 0.05 or less was considered statistically
signiﬁcant for all analyses.
ROLE OF THE FUNDING SOURCE. The stent manu-
facturers who funded the trial had contributing roles
in the design of the trial and in the collection of
the data. Harvard Clinical Research Institute was
responsible for the scientiﬁc conduct of the trial and
independent analysis of the data. RWY, JMM, and LM
had full access to all the data used in the study, and
the study publications committee (including RWY,
DJK, JMM, and LM) had ﬁnal responsibility for the
decision to submit for publication.
RESULTS
STUDY POPULATION. Of 11,648 patients randomized
in the DAPT Study, 3,576 (30.7%) presented with
acute MI with the remainder presenting without
evidence of MI at the index procedure (Figure 1).
Among MI patients, 1,680 (47%) presented with initial
ST-elevation MI, whereas the remainder presented
with non–ST-elevation MI. Among patients with no
MI, 1,821 (22.6%) were classiﬁed as having unstable
angina without cardiac biomarker elevation.Patients with MI had higher rates of smoking,
whereas patients with no MI were older (average age,
63 vs. 58 years; p < 0.001); more often female; and
had higher rates of diabetes, peripheral arterial dis-
ease, and prior PCI. Characteristics were evenly
balanced across randomization arms for patients with
and without MI (Table 1). Rates of prasugrel use at
randomization were higher among patients with
MI compared with those without (34.0% vs. 30.6%,
respectively; p < 0.001). Among patients with MI,
27.6% received BMS only and 72.4% received DES,
compared with 8.7% and 91.3%, respectively, among
patients with no MI. Lesions were less complex
among patients with MI, with lower rates of heavy
calciﬁcation, tortuosity, and left main and in-stent
restenosis lesions.
OUTCOMES COMPARING PATIENTS WITH VERSUS
WITHOUT ACUTE MI. Patients presenting with MI
had signiﬁcantly higher rates of deﬁnite or probable
stent thrombosis (1.2% vs. 0.7%; p ¼ 0.01) between 12
and 30 months than patients without MI (Table 2).
Rates of MACCE were similar for patients with versus
without MI (5.4% vs. 4.9%; p ¼ 0.24). Among the
components of MACCE, rates of subsequent MI were
higher for patients with MI compared with those
without MI (3.7% vs. 2.8%; p ¼ 0.01) (Figure 2B),
which was primarily related to higher rates of stent-
thrombosis–associated MI (1.2% vs. 0.7%; p ¼ 0.005).
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2216The rates of death and stroke were no different be-
tween patients with versus without MI. In both
groups, nonfatal MI was the predominant contributor
to MACCE in follow-up, accounting for 69% of events
in the MI group, and 57% of events in the no MI
group.
GUSTO moderate or severe bleeding occurred less
often in patients with MI (1.4%) as compared with
those without (2.1%; p ¼ 0.008) between 12 and 30
months after initial presentation. Similar results were
observed on the basis of classiﬁcation by the Bleeding
Academic Research Consortium deﬁnitions. Fatal
bleeding was rare and not signiﬁcantly different be-
tween patients with versus without MI (0.17% vs.
0.08%; p ¼ 0.15).
CONSISTENCY OF TREATMENT EFFECT OF CONTINUED
THIENOPYRIDINE IN PATIENTS PRESENTING WITH AND
WITHOUT MI. The relative reduction of stent throm-
bosis associated with continued thienopyridine wasTABLE 2 Ischemic and Bleeding Outcomes in all Randomized
Patients, According to Acute Myocardial Infarction Status,
From 12 to 30 Months After Coronary Stent Treatment
Myocardial
Infarction at
Presentation
(n ¼ 3,576)
No Myocardial
Infarction at
Presentation
(n ¼ 8,072)
Log-rank
p Value
Stent thrombosis
(deﬁnite or probable)
41 (1.19) 56 (0.72) 0.01
Deﬁnite 39 (1.14) 47 (0.60) 0.003
Probable 3 (0.09) 9 (0.12) 0.67
MACCE (death, MI, or stroke) 186 (5.37) 381 (4.85) 0.24
Death 51 (1.48) 139 (1.77) 0.26
Cardiac 27 (0.78) 74 (0.95) 0.39
Vascular 4 (0.12) 6 (0.08) 0.52
Noncardiovascular 20 (0.58) 59 (0.76) 0.31
MI 127 (3.69) 217 (2.78) 0.01
Stent thrombosis related 41 (1.19) 52 (0.67) 0.005
Nonstent thrombosis
related
87 (2.52) 171 (2.19) 0.27
Stroke (total) 25 (0.73) 66 (0.85) 0.51
Ischemic 19 (0.55) 48 (0.62) 0.69
Hemorrhagic 7 (0.20) 16 (0.21) 0.99
Type uncertain 0 (0.00) 2 (0.03) 0.35
GUSTO moderate or severe
bleeding
48 (1.39) 167 (2.14) 0.008
GUSTO moderate 26 (0.75) 117 (1.50) 0.001
GUSTO severe 22 (0.64) 51 (0.66) 0.93
BARC types 2, 3, or 5 111 (3.22) 339 (4.34) 0.005
BARC type 2 61 (1.77) 185 (2.37) 0.04
BARC type 3 47 (1.36) 165 (2.12) 0.007
BARC type 5
(fatal bleeding)
6 (0.17) 6 (0.08) 0.15
Values are n (% [Kaplan-Meier estimates]).
BARC ¼ Bleeding Academic Research Consortium; GUSTO ¼ Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; MACCE ¼
major adverse cardiovascular and cerebrovascular event(s); MI ¼ myocardial
infarction.similar for patients with and without MI (interaction
p ¼ 0.69 for stent thrombosis) (Figure 2). In patients
with MI, the rate of stent thrombosis was 0.5% for
continued thienopyridine versus 1.9% for placebo
(HR: 0.27; 95% CI: 0.13 to 0.57; p < 0.001), whereas for
patients with no MI, the corresponding rates were
0.4% versus 1.1%, respectively (HR: 0.33; 95% CI:
0.18 to 0.60; p < 0.001). For the composite endpoint
of MACCE, continued thienopyridine was associated
with a similar directional beneﬁt but greater magni-
tude reductions for patients with MI (3.9% vs. 6.8%;
HR: 0.56; 95% CI: 0.42 to 0.76; p < 0.001) compared
with those without MI (4.4% vs. 5.3%; HR: 0.83; 95%
CI: 0.68 to 1.02; p ¼ 0.08; interaction p ¼ 0.03)
(Figure 3).
Continued thienopyridine consistently reduced MI
in patients with and without MI (interaction p ¼ 0.15)
(Central Illustration). Among patients with MI, the rate
of MI was 2.2% for continued thienopyridine versus
5.2% for placebo (HR: 0.42; 95% CI: 0.29 to 0.62;
p < 0.001). In patients with no MI, the rate of MI was
2.1% for continued thienopyridine versus 3.5% for
placebo (HR: 0.60; 95% CI: 0.45 to 0.79; p < 0.001).
For both groups, the reduction in MI was related to
the prevention of both stent thrombosis- and non-
stent thrombosis-related events (Table 3).
Continued thienopyridine increasedmajor bleeding
in both patients with MI (1.9% vs. 0.8%; HR: 2.38; 95%
CI: 1.28 to 4.43; p ¼ 0.005) and those without MI (2.6%
vs. 1.7%; HR: 1.53; 95% CI: 1.12 to 2.08; p ¼ 0.007;
p ¼ 0.21 for interaction). Among patients with MI, the
rates of all-cause death were 1.4% in the continued
therapy group versus 1.6% in the placebo group
(HR: 0.87; 95% CI: 0.50 to 1.50; p ¼ 0.61). Among pa-
tients with no MI, the rates of death were 2.1% for
continued thienopyridine group versus 1.5% for pla-
cebo (HR: 1.43; 95% CI: 1.02 to 2.00; p¼ 0.04; effect for
MI vs. no MI interaction p ¼ 0.13).
SENSITIVITY ANALYSES. In patients with and
without MI, reduction in stent thrombosis with
continued thienopyridine was consistent for DES-
treated patients and BMS-treated patients (interac-
tion p ¼ 0.87 for MI patients; interaction p ¼ 0.12
for no MI patients) (Online Tables 1 to 6). Continued
thienopyridine was also associated with consistent
reductions in stent thrombosis and MI across different
thienopyridine types, prasugrel and clopidogrel (MI
patients: interaction p ¼ 0.86 for stent thrombosis,
interaction p ¼ 0.22 for MI; no MI patients: interaction
p ¼ 0.97 for stent thrombosis, interaction p ¼ 0.10 for
MI for patients without MI). Moderate or severe
bleeding with continued thienopyridine was also
increased to a similar degree with prasugrel or
FIGURE 2 Cumulative Incidence of Stent Thrombosis According to Randomization Arm
for Patients With and Without Acute Myocardial Infarction
Patients Presenting With Myocardial Infarction 
Patients Presenting Without Myocardial Infarction
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Placebo
Thienopyridine vs. Placebo, 0.5% vs. 1.9%;
Hazard Ratio 0.27, p<0.001 
Thienopyridine vs. Placebo, 0.4% vs. 1.1%;
Hazard Ratio 0.33, p<0.001 
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Randomization occurred 12 months after initial presentation. Endpoint includes deﬁnite or
probable stent thrombosis as assessed according to the criteria of the Academic Research
Consortium. The effect of continued thienopyridine on stent thrombosis was similar for
patients with (A) versus without (B) myocardial infarction at presentation (interaction
p ¼ 0.69).
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2217clopidogrel among patients with MI (interaction p ¼
0.09) and those without MI (interaction p ¼ 0.13).
Finally, when excluding patients who received
paclitaxel-eluting stents, the results were similar to
the main study ﬁndings, with continued thienopyr-
idine having a similar effect on stent thrombosis
(interaction p ¼ 0.34) and MI (interaction p ¼ 0.57) for
patients with and without MI.
DISCUSSION
In this analysis from the DAPT Study, patients pre-
senting with acute MI who survived the ﬁrst year after
PCI without a major ischemic or bleeding event
continued to be at higher risk for subsequent ischemic
events, including stent thrombosis and MI, compared
with those presenting without MI. Continued thieno-
pyridine therapy beyond 12 months was associated
with signiﬁcant reductions in stent thrombosis and MI
and an increase in bleeding in both groups.
These ﬁndings have important implications for
the management of dual antiplatelet therapy in
patients undergoing PCI. As demonstrated here and
in prior studies, patients presenting with MI repre-
sent a subgroup that continues to experience higher
rates of stent thrombosis and MI more than 1 year
removed from their initial event (2). As such, MI
patients are among those that may derive particular
beneﬁt from extension of thienopyridine therapy.
Current guidelines recommend only a year of dual
antiplatelet therapy after an acute coronary event
(4–6). Our data suggest that if patients undergoing
PCI after MI have not experienced a major ischemic
or bleeding event within the ﬁrst year of follow-up,
continuation of dual antiplatelet therapy beyond 1
year is associated with a reduced risk of stent
thrombosis and MI. Continued thienopyridine ther-
apy over an 18-month treatment period was asso-
ciated with an absolute risk reduction of 2.9% for
MI and 1.4% for stent thrombosis, and an absolute
risk increase of 1.1% for moderate or severe
bleeding (0.9% for moderate and 0.2% for severe)
among patients with MI.
Patients undergoing PCI without MI had lower
long-term ischemic event rates compared with MI
patients, yet the reduction in stent thrombosis and
MI with continued dual antiplatelet therapy was
consistent among patients not presenting with MI.
Compared with 12 months of treatment, continued
thienopyridine for 30 months was associated with an
absolute risk reduction of 1.4% for MI and 0.7% for
stent thrombosis, and an absolute risk increase of
0.9% for moderate or severe bleeding (0.6% for
moderate and 0.3% for severe) in this population.A lesser magnitude reduction in MACCE was
observed with continued thienopyridine therapy
among patients without compared with those with
MI at presentation, caused in part by the overall
lower rates of nonfatal MI in follow-up among pa-
tients without MI, but also by an increase in death for
patients without MI receiving continued thienopyr-
idine. As previously described (1), a higher rate of
noncardiovascular death was observed among DES-
treated patients assigned to continued thienopyr-
idine. Masked adjudication of all noncardiovascular
deaths determined that most of these deaths were
not preceded by a documented bleeding event. A
meta-analysis of more than 69,000 patients from
randomized clinical trials comparing different dura-
tions of dual antiplatelet therapy across a variety of
clinical indications, including more than 39,000 pa-
tients with coronary artery disease, showed no
FIGURE 3 Cumulative Incidence of Major Adverse Cardiovascular and
Cerebrovascular Events According to Randomization Arm for Patients With and Without
Acute Myocardial Infarction
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Hazard Ratio 0.83, p=0.08
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Major adverse cardiovascular and cerebrovascular event(s) (MACCE) was deﬁned as the
composite of death, myocardial infarction, or stroke. Randomization occurred 12 months
after initial presentation. The effect of continued thienopyridine on MACCE was greater for
patients with myocardial infarction (A) compared with patients without myocardial
infarction (B) at presentation (interaction p ¼ 0.03).
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all-cause or noncardiovascular death (15), suggesting
that the ﬁndings among DES patients, concentrated
among those without MI, may have been caused by
chance. Patients without MI were older and had more
comorbidities (diabetes, peripheral and cerebrovas-
cular disease). These factors may have led to the
higher proportion of noncardiac events in patients
without MI; it is also possible that these factors
contributed to more frequent bleeding events in this
same group.
In light of greater reduction in quality of life
expectancy associated with major ischemic events,
as compared with bleeding events of this fre-
quency and magnitude (16), our results suggest that
among acute MI patients undergoing PCI, there is a
strong beneﬁt for continuing thienopyridine therapybeyond 12 months after presentation. However, even
among patients without MI, the risk-beneﬁt balance
may favor continuation of thienopyridine therapy
beyond 12 months for those who are able to tolerate
the ﬁrst year of dual antiplatelet therapy. The results
also suggest that the beneﬁts of continued thieno-
pyridine therapy observed in patients with and
without MI were consistent whether or not patients
received clopidogrel or prasugrel, or whether they
received paclitaxel- or non–paclitaxel-eluting stents.
Furthermore, the beneﬁt of receiving continued
thienopyridine therapy in patients with and without
MI was in the prevention of nonfatal MI in follow-up,
both related to and not related to stent thrombosis.
The absolute reduction in nonstent thrombosis-
related MI was 1.5% in the MI group and 0.6% in
the no MI group, accounting for roughly one-half
of the reduction in nonfatal MI in both groups.
These ﬁndings suggest that continued thienopyridine
therapy has an important effect beyond stent
thrombosis on secondary prevention of future MIs
after PCI.
Several prior analyses have compared different
durations of dual antiplatelet therapy after coronary
stent procedures (17–21) including examining the
consistency of treatment effects on patients with
and without acute coronary syndromes (22). How-
ever, the DAPT study is unique in several regards.
First, it is the largest study to date, having been
powered to examine rare events, such as stent
thrombosis. Next, patients enrolled in the DAPT
Study comprised a broad range of presentations
(23), including a very high proportion with acute
coronary syndromes, including ST-segment
elevation MI, allowing for more precise estimates
of the effect of continued thienopyridine therapy in
high-risk patients similar to those seen in clinical
practice. The study population represents
the largest cohort to date to evaluate the effect of
continued thienopyridine therapy after coronary
stents in patients with and without MI.
Beyond randomized studies focused on coronary
stents, the largest prior study of extended duration
clopidogrel in subjects with symptomatic, but stable,
cardiovascular disease or risk factors for cardiovas-
cular disease was negative regarding reduction in
cardiovascular risk (7). Within this trial, the subset of
patients with prior documented symptomatic car-
diovascular disease (mainly coronary artery disease)
appeared to beneﬁt from extended therapy (24),
whereas the asymptomatic subset did not. Our results
are consistent with these prior results, and suggest
that among symptomatic patients with coronary ar-
tery disease, prolonged thienopyridine therapy may
CENTRAL ILLUSTRATION Duration of Dual Antiplatelet Therapy for Patients With and Without Myocardial Infarction
Yeh, R.W. et al. J Am Coll Cardiol. 2015; 65(20):2211–21.
Cumulative incidence of myocardial infarction according to randomization arm for patients with (top) and without (bottom) acute myocardial infarction.
Randomization occurred 12 months after initial presentation. The effect of continued thienopyridine on myocardial infarction was similar for patients with
versus without myocardial infarction at presentation (interaction p ¼ 0.15).
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TABLE 3 Ischemic and Bleeding Outcomes 12 to 30 Months After
Coronary Stent Treatment in all Randomized Patients, Stratiﬁed by Presentation
With Versus Without Acute Myocardial Infarction
Continued
Thienopyridine Placebo
Hazard Ratio
(95% CI)
Stratiﬁed
Log-Rank
p Value
P Value
for
Interaction
Deﬁnite or probable
stent thrombosis
0.69
MI group 9 (0.5) 32 (1.9) 0.27 (0.13–0.57) <0.001
No MI group 14 (0.4) 42 (1.1) 0.33 (0.18–0.60) <0.001
MACCE 0.03
MI group 69 (3.9) 117 (6.8) 0.56 (0.42–0.76) <0.001
No MI group 175 (4.4) 206 (5.3) 0.83 (0.68–1.02) 0.08
MI 0.15
MI group 39 (2.2) 88 (5.2) 0.42 (0.29–0.62) <0.001
No MI group 82 (2.1) 135 (3.5) 0.60 (0.45–0.79) <0.001
Stent thrombosis-related MI 0.86
MI group 9 (0.5) 32 (1.9) 0.27 (0.13–0.57) <0.001
No MI group 12 (0.3) 40 (1.0) 0.30 (0.16–0.57) <0.001
Nonstent thrombosis-
related MI
0.24
MI group 31 (1.8) 56 (3.3) 0.53 (0.34–0.83) 0.01
No MI group 73 (1.9) 98 (2.5) 0.74 (0.54–1.00) 0.047
Death 0.13
MI group 24 (1.4) 27 (1.6) 0.87 (0.50–1.50) 0.61
No MI group 82 (2.1) 57 (1.5) 1.43 (1.02–2.00) 0.04
Cardiac death 0.33
MI group 11 (0.6) 16 (0.9) 0.67 (0.31–1.44) 0.30
No MI group 38 (1.0) 36 (0.9) 1.05 (0.66–1.65) 0.48
Noncardiovascular death 0.23
MI group 11 (0.6) 9 (0.5) 1.19 (0.49–2.87) 0.69
No MI group 41 (1.0) 18 (0.5) 2.26 (1.30–3.94) 0.002
GUSTO moderate or
severe bleeding
0.21
MI group 34 (1.9) 14 (0.8) 2.38 (1.27–4.43) 0.005
No MI group 101 (2.6) 66 (1.7) 1.53 (1.12–2.08) 0.007
GUSTO moderate
bleeding
0.06
MI group 21 (1.2) 5 (0.3) 4.10 (1.55–10.87) 0.002
No MI group 70 (1.8) 47 (1.2) 1.48 (1.03–2.15) 0.04
GUSTO severe bleeding 0.86
MI group 13 (0.7) 9 (0.5) 1.41 (0.60–3.29) 0.43
No MI group 31 (0.8) 20 (0.5) 1.54 (0.88–2.70) 0.13
BARC 2, 3, or 5 0.666
MI group 76 (4.3) 35 (2.1) 2.14 (1.43–3.19) <0.001
No MI group 223 (5.7) 116 (3.0) 1.93 (1.55–2.42) <0.001
Values are n (% [Kaplan-Meier estimates]), unless otherwise noted.
Abbreviations as in Table 2.
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subjects without MI represented a higher-risk popu-
lation than subjects studied in prior trials of stable
angina, because the group included a large number
of subjects with unstable angina, all with history of
prior coronary revascularization procedures, and
with concomitant cardiac risk factors. These ﬁndings
suggest that patients previously considered “stable”a full year removed from PCI for acute or stable
presentations are still subject to preventable risks
of future MI, not directly related to the stent proce-
dure. The 1-year follow-up after coronary stenting
thus provides an important contact in which to
intervene to continue thienopyridine therapy in
those subjects who have tolerated treatment without
major bleeding.
STUDY LIMITATIONS. First, because the study ran-
domized only those patients who did not sustain a
major event during the ﬁrst year after PCI and were
compliant with therapy, the study results are only
relevant to patients who have achieved a similar
milestone. Next, the study only included thienopyr-
idine P2Y12 inhibitors; a related randomized study of a
different P2Y12 inhibitor, ticagrelor, found that sub-
jects with prior MI beneﬁted from extended dual an-
tiplatelet therapy with this agent (25). We conducted
several exploratory analyses examining the consis-
tency of the treatment effect of continued thieno-
pyridine on the basis of stent type and drug type.
However, these analyses were not pre-speciﬁed or
speciﬁcally powered to assess interactions, and
should therefore be interpreted accordingly. Finally,
the results shown represent aggregated ﬁndings for
patients with and without MI. Additional risk factors
may help to identify smaller subgroups of patients
who may experience a different balance in the risks
and beneﬁts of continued thienopyridine therapy af-
ter 12 months.
CONCLUSIONS
The continuation of thienopyridine-plus-aspirin
therapy beyond 1 year after coronary stenting
reduced ischemic events in patients both with and
without acute MI at presentation, but increased
bleeding compared with treatment with aspirin alone.
Although patients presenting with MI had higher
risks of subsequent ischemic events, the effect of
continued treatment in reducing stent thrombosis
and MI was nevertheless consistent among patients
not presenting with MI.
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PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE:
Continuation of thienopyridine therapy beyond 12 months
after coronary stent implantation reduces stent throm-
bosis and myocardial infarction in patients with acute
coronary syndromes or stable ischemic heart disease un-
dergoing percutaneous revascularization, but increases
the risk of bleeding.
TRANSLATIONAL OUTLOOK: Further studies are
needed to identify individual patient characteristics
associated with thrombotic and hemorrhagic events to
guide individualized decisions on the duration of dual
antiplatelet therapy for patients in speciﬁc clinical
situations.
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